Introduction {#s1}
============

*Xist* is a 17 kb long noncoding RNA that acts through specific interactions between its distinct RNA domains and nuclear effector proteins. The *Xist* RNA-associated protein complex was identified in 2015 using both genetic and affinity-based methods, and consists of multiple pleiotropic proteins, many of which are highly conserved throughout evolution and act on chromatin structure and gene regulation in myriad systems ([@bib2]; [@bib7]; [@bib36]; [@bib37]; [@bib40]; [@bib39]). This suggests that *Xist* evolved the ability to bind these proteins in the eutherian mammals, coopting those which evolved initially to perform other epigenetic functions. *Xist* evolved in the eutherian clade through exaptation of a combination of coding genes that were pseudogenized, as well as transposable elements (TEs) that inserted into this locus. *Xist* contains six tandem repeat regions (A-F), all of which show sequence similarity to TEs, suggesting they arose from eutheria-specific TE insertions ([@bib12]). One of these is the A-repeat, which is essential for gene silencing. When this \~500 bp region is deleted, *Xist* RNA coats the X chromosome, but silencing and reorganization of the X does not follow ([@bib54]; [@bib15]). The A-repeat sequence is thought to derive from the insertion and duplication of an endogenous retrovirus (ERV), a class of TEs present in many copies throughout the genome ([@bib12]). In general, lncRNAs are not well-conserved compared to protein-coding genes but are enriched for TE content, suggesting they may be able to rapidly evolve functional domains by exapting protein- and nucleic acid-binding activity from entire TEs that colonize their loci ([@bib20]; [@bib23]). Understanding how the *Xist* RNA sequence was evolutionarily stitched together from these existing building blocks to gain protein-binding potential is of great interest towards understanding dosage compensation and lncRNA-mediated gene regulation genome-wide.

Spen (also known as SHARP, MINT) is a \~ 400 kDa *Xist* RNA binding protein (RBP) that contains four canonical RNA binding domains, as well as a SPOC domain to facilitate protein-protein interactions. Spen is a co-repressor that binds to several chromatin remodeling complexes, including histone deacetylases (HDACs), and the NuRD complex ([@bib36]; [@bib46]). Though now recognized for its central role in the eutherian-specific XCI process, Spen is an ancient protein that plays roles in gene repression during development in species including *Drosophila *and *Arabidopsis*, in addition to mice and humans ([@bib46]; [@bib55]; [@bib24]; [@bib53]; [@bib3]). Spen binds directly to the A-repeat of *Xist* RNA and *Spen* inactivation abrogates silencing of multiple X-linked genes, suggesting that the RNA-protein interaction between the A-repeat and Spen is an early and essential step in XCI ([@bib7]; [@bib36]; [@bib40]; [@bib31]).

Results {#s2}
=======

To test the effect of Spen loss on gene regulation and chromosome accessibility during XCI and genome-wide during development, we performed ATAC-seq ([@bib6]) in haploid mouse embryonic stem cells (mESCs) harboring a doxycycline-inducible *Xist* transgene either in the wild-type (WT) context or with a full deletion of *Spen* (*Spen* KO) ([@bib40]; [Figure 1a](#fig1){ref-type="fig"}). Following 48 hr of *Xist* induction, WT cells demonstrated loss of chromatin accessibility at the majority of loci on the X chromosome ([Figure 1b--c](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1a,b](#fig1s1){ref-type="fig"}). In two independent *Spen* KO mESC clones, we found no X chromosome site that is reproducibly silenced upon *Xist* induction, suggesting that Spen is absolutely required for gene silencing at the level of chromatin accessibility ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}). This complete failure of XCI, combined with Spen's direct binding to the A-repeat region ([@bib7]; [@bib36]; [@bib40]), confirms that Spen's recruitment to the inactivating X chromosome is early and essential for XCI ([@bib10]; [@bib41]).

![*Spen* knockout blocks XCI chromosome-wide and leads to derepression of autosomal ERVs.\
(**a**) Diagram of experimental set up. *Spen* KO mESCs are cultured +/- Doxycycline for 48 hr to induce *Xist* expression and then ATAC-seq is performed. We ask which sites are de-repressed in *Spen* KO compared to WT cells both during XCI and on the autosomes. (**b**) Log~2~ ratio of ATAC-seq signal in +Dox and --Dox samples at all ATAC-seq peaks on the X chromosome in WT and *Spen* KO mESCs. Two independent *Spen* KO mESC clones are shown. (**c**) Same as in b for all autosomal peaks. (**d**) Heatmap showing ATAC-seq signal for all differential peaks between WT and *Spen* KO mESCs. Values depict the z-scored value for normalized ATAC-seq reads within each peak for WT, *Spen* KO Cl2, and *Spen* KO Cl3 cells (with two replicates each). (**e**) Pie charts depicting the proportion of ATAC-seq peaks that cover each genomic region annotation. Annotations are derived from HOMER. (**f**) Genome Ontology enrichment (by HOMER) for all sites gaining accessibility in *Spen* KO mESCs compared to WT (*n* = 288). Plotted is the --log~10~ p-value for enrichment. *P* values (one-sided binomial) are corrected for multiple hypothesis testing using the Benjamini-Hochberg correction. (**g**) Two example ERVK regions on chromosome 16 (left) and chromosome 1 (right) showing a gain in chromatin accessibility specifically in two clones of *Spen* KO mESCs. Shown are tracks of uniquely mapping reads (top) and tracks where multimapping reads are randomly assigned to one location (bottom).](elife-54508-fig1){#fig1}

Despite recent focus on Spen's role in XCI, Spen is an ancient protein that is known to act as an important RNA-protein scaffold in developmental processes in many species ([@bib46]; [@bib55]; [@bib24]; [@bib53]; [@bib3]). Thus, how *Xist* evolved the ability to recruit Spen is of great interest. We hypothesized that understanding Spen's role in autosomal gene regulation and its target specificity might lend clues into how Spen was exapted to participate in the Eutherian-specific process of XCI ([Figure 1a](#fig1){ref-type="fig"}). Comparison of ATAC-seq data in WT and *Spen* KO mESCs revealed 288 sites on the autosomes that gain accessibility in two clones of *Spen* KO mESCs, compared to only 147 sites that lose accessibility ([Figure 1d](#fig1){ref-type="fig"}). This observation is consistent with chromatin de-repression in the absence of Spen's repressive function. The DNA elements that were more accessible in *Spen* KO mESCs are almost all distal to transcriptional start sites (TSS), in contrast to unchanging peaks and those that are less accessible, which encompassed both promoters and distal sites ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). This indicated that DNA elements regulated by Spen on the autosomes are not found at gene promoters, but rather are found in heterochromatic, gene-poor regions.

To better understand Spen's autosomal targets, we performed genome ontology enrichment for the sites that are de-repressed in *Spen* KO mESCs using HOMER. While the set of sites confidently gaining accessibility in both *Spen* KO clones is relatively small, it showed a striking enrichment for TE-derived long terminal repeat (LTR) elements ([Figure 1e](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}). When we looked more closely at subsets of these annotations, we found an enrichment specifically for endogenous retrovirus K (ERVK) TEs in these sites, which is reproduced in two independent *Spen* KO clones ([Figure 1f](#fig1){ref-type="fig"}). These ERVKs are enriched specifically for LTR elements in the RLTR13, RLTR9, and early transposon (ETn) families ([Figure 1f](#fig1){ref-type="fig"}). ERV-derived sequences in the genome have recently been shown to play important roles in genome regulation in embryonic cell types, serving as binding sites for transcription factors, indicating that Spen loss may activate ectopic regulatory regions ([@bib4]; [@bib16]; [@bib33]). Because sequencing reads coming from TEs in the genome do not map uniquely, it is difficult to accurately quantify reads coming from a given ERV subfamily while also mapping them to the correct element. We thus mapped ATAC-seq reads to the genome, while either keeping only uniquely mapping reads, or allowing multi-mapping reads to randomly map to one location. Both of these methods revealed the same trend, demonstrating the de-repression of a subset of ERVK elements in *Spen* KO mESCs ([Figure 1g](#fig1){ref-type="fig"}).

The observation that TE-derived elements were activated in *Spen* KO mESCs was intriguing, given that the A-repeat region of Xist is itself believed to be derived from an ancient TE insertion ([@bib12]). It has been posited that TEs, upon insertion into pseudogenes or non-coding loci may contribute functional protein-binding domains to noncoding RNAs ([@bib20]). Indeed, noncoding RNAs, including Xist, are enriched for TE content ([@bib23]). Furthermore, it is known that in a very distantly related species, the model plant *Arabidopsis*, the Spen homologs *fca* and *fpa* bind to and regulate transcription of TEs in the genome ([@bib3]). Therefore, Spen's ability to regulate a subset of ERVK families may explain Spen's ability to recognize the A-repeat and interact directly with it.

In mESCs, the majority of TEs, including ERVKs, are silenced by histone H3 lysine nine trimethylation (H3K9me3). When members of the TE silencing machinery, such as Kap1 and Setdb1, are inactivated, H3K9me3 is lost, and these TE insertions can be expressed and function as ectopic promoters and enhancers ([@bib34]; [@bib43]; [@bib22]; [@bib29]). We hypothesized that in the absence of Spen and its protein partners, these ERVKs would lose H3K9me3 and gain histone modifications associated with active gene expression ([@bib59]; [@bib36]; [@bib46]).

Indeed, ChIP-seq experiments revealed that DNA elements gaining accessibility in *Spen* KO showed a dramatic loss of H3K9me3 and a gain of both histone H3 lysine 27 acetylation (H3K27Ac) and histone H3 lysine four trimethylation (H3K4me3) marks ([Figure 2a,b](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1a--c](#fig2s1){ref-type="fig"}). Conversely, H3K9me3 peaks that are lost in *Spen* KO mESCs are enriched for ERVKs, and sites that gain the enhancer mark H3K27Ac are enriched for ERVKs including ETn elements ([Figure 2c,d](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1d--f](#fig2s1){ref-type="fig"}). This demonstrates that at the level of chromatin modifications, a subset of ERVK elements are de-repressed when Spen is lost in mESCs. To test whether these ERVK elements are upregulated at the level of transcription, we performed RNA-seq in WT and *Spen* KO mESCs ([Figure 2---figure supplement 1a,e](#fig2s1){ref-type="fig"}; [Figure 2---figure supplement 2a--c](#fig2s2){ref-type="fig"}). At the RNA level, the ERVK elements that gain accessibility also have higher expression in *Spen* KO mESCs ([Figure 2b,e](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). Genome-wide there is a very small increase in expression of all ERVKs, particularly the class of ETnERV2s, indicating that only a subset of these families are affected by the loss of Spen in mESCs ([Figure 2f,g](#fig2){ref-type="fig"}). This is true using our multimapping read assignment strategy, as well as a published method for TE mapping, MMR ([@bib21]; [Figure 2---figure supplement 1g--i](#fig2s1){ref-type="fig"}).

![*Spen* knockout leads to gain of histone acetylation and loss of H3K9me3-mediated repression at ERVKs.\
(**a**) Average diagrams and heatmaps showing the read count per million mapped reads for ATAC-seq and ChIP-seq plotted over all ATAC-seq peaks that gain accessibility in *Spen* KO mESCs (*n* = 288) (+ / - 2 kb). From left to right are ATAC-seq, Oct4 ChIP-seq, H2K27Ac ChIP-seq, H3K4me3 ChIP-seq, and H3K9me3 ChIP-seq. Data is shown for WT mESCs (green) and *Spen* KO clone 2 mESCs (orange). For the heatmaps, each row represents one peak. (**b**) An example of an ETnERV2 element on chromosome four that shows a gain of chromatin accessibility, RNA expression, H3K27Ac ChIP-seq, Oct4 ChIP-seq, and a loss of H3K9me3 ChIP-seq in *Spen* KO mESCs compared to WT. (**c**) Genome Ontology enrichment (by HOMER) for all sites gaining H3K27Ac ChIP-seq signal in *Spen* KO mESCs compared to WT (*n* = 1125 sites). Plotted is the --log~10~ p-value for enrichment. *P* values (one-sided binomial) are corrected using the Benjamini-Hochberg correction. (**d**) Genome Ontology enrichment (by HOMER) for all sites losing H3K9me3 ChIP-seq signal in *Spen* KO mESCs compared to WT (*n* = 660 sites). Plotted is the --log~10~ p-value for enrichment. *P* values (one-sided binomial) are corrected using the Benjamini-Hochberg correction. (**e**) Expression of ERVKs gaining accessibility in *Spen* KO mESCs in WT mESCs (green) and *Spen* KO mESCs (orange). Shown is the log~2~ transformed normalized RNA-seq read counts. For all boxplots, the thick line represents the median, while the box gives the IQR. *P* values are calculated using a two-tailed T test. (**f**) Same as in d for all ERVKs, genome wide. (**g**) Same as in e for all ETn-ERV2s. (**h**) Diversity of repeat for all ERVK elements that gain accessibility in *Spen* KO mESCs (purple) and all ERVK elements (gray). Percent diversity represents the percentage of the sequence that has diverged from the ancestral TE insertion. Percentages come from RepeatMasker.](elife-54508-fig2){#fig2}

Retrotransposons are parasitic elements whose insertion and propagation in cells depletes cellular resources and disrupts endogenous gene expression. In order for the cell to handle these parasitic elements, pathways have evolved to shut down these transposons at the level of the DNA locus and the RNA transcript. ERVK insertions that are more similar to the original TE sequence pose more of a threat to cells, as they are more likely to be mobile and able to replicate. Thus, we compared the sequence diversity of the ERVKs upregulated in S*pen* KO to those not upregulated in *Spen* KO, and found that those repressed by Spen have diverged less than those that are not repressed by Spen ([Figure 2h](#fig2){ref-type="fig"}). The lower diversity indicates that Spen targets more recent ERVK insertions. Furthermore, we found that genes involved in the innate cellular immunity pathway, which responds to retroviral RNA presence, are modestly upregulated in *Spen* KO mESCs ([Figure 2---figure supplement 2d](#fig2s2){ref-type="fig"}). These data suggest that Spen represses young, more intact ERVKs, and when Spen is inactivated, the cell responds to the presence of those RNA transcripts to attempt to silence them.

TE insertions are enriched for transcription factor binding motifs, and it has been suggested that insertion of many elements of the same family within the genome may have led to the evolution of transcription factor-based regulatory networks ([@bib4]; [@bib50]; [@bib51]). ERVK, and more specifically ETn, elements are enriched for binding sites for Oct4, one of the most critical transcription factors for regulation of the pluripotent state ([@bib4]; [@bib44]). Oct4 plays a critical role in balancing the expression of pro-self renewal and pro-differentiation genes in mESCs. We find that the Oct4 binding motif is enriched at DNA elements gaining accessibility in *Spen* KO mESCs, and Oct4 occupancy increases at these loci as shown by ChIP-seq ([Figure 2a](#fig2){ref-type="fig"}). The ability of this core stemness factor to bind to these TE elements suggests that their misregulation in *Spen* KO mESCs may affect the self-renewal or differentiation programs within these cells. GO term analysis revealed that genes downregulated in *Spen* KO mESCs are enriched for early developmental terms, indicating that these cells may be deficient in early lineage commitment ([Figure 2---figure supplement 2e--f](#fig2s2){ref-type="fig"}). We found that *Spen* KO mESCs downregulated specific genes associated with early differentiation and upregulated genes associated with self-renewal ([Figure 2---figure supplement 3a](#fig2s3){ref-type="fig"}).

Because the balance in the pluripotency transcriptional network is disrupted in *Spen* KO mESCs, we hypothesized that differentiation may be blocked. To test whether *Spen* KO mESCs can spontaneously differentiate when deprived of self-renewal signals, we removed leukemia inhibitory factor (LIF) from the media and allowed cells to grow for 6 days. After 6 days, WT mESCs downregulated pluripotency factors such as Oct4 and expressed early differentiation markers such as Nestin. In contrast, *Spen* KO mESCs maintained Oct4 expression and mESC morphology despite LIF removal ([Figure 2---figure supplement 3b,c](#fig2s3){ref-type="fig"}). We then tested whether *Spen* KO mESCs can be directed to differentiate toward the neurectoderm fate, by driving differentiation toward neural progenitor cells. After 14 days of differentiation, WT cells express Nestin and have NPC morphology while *Spen* KO mESCs do not ([Figure 2---figure supplement 3d](#fig2s3){ref-type="fig"}). Furthermore, we observed massive cell death during *Spen* KO mESC differentiation, finding that by day 10 of directed differentiation, 100% of cells were no longer viable ([Figure 2---figure supplement 3e](#fig2s3){ref-type="fig"}). These results support the results from RNA-seq that suggest that Spen loss leads to a failure to differentiate past the pluripotent state.

We next asked whether Spen represses ERVK loci directly or indirectly. Though we observe changes in chromatin accessibility and covalent histone modifications at these loci when Spen is knocked out, Spen is an RBP that does not bind to chromatin directly. We hypothesized that Spen may recognize *ERVK* RNAs transcribed at these TE loci and recruit chromatin silencing machinery to them, performing a surveillance role against aberrant transcription of these parasitic elements. Thus if Spen is regulating these ERVK loci directly, we would expect that regulation to be RNA-dependent ([Figure 3a](#fig3){ref-type="fig"}).

![Spen's RNA binding domains bind specifically to *ERV* RNAs in vivo.\
(**a**) Diagram of irCLIP-seq rationale. irCLIP-seq was performed for the Spen RNA binding domains to identify direct RNA binding partners of Spen genome-wide. (**b**) Pie chart showing the number of irCLIP-seq clusteres called on TE RNAs and mRNAs and lncRNAs. (**c**) Pie chart showing the number of RNA transcripts containing at least one irCLIP-seq cluster in TEs and mRNAs and lncRNAs. (**d**) Binding strength of RRM2-4 for the top 50 Spen-bound RNAs. *Xist* (\#1) and *Spen* (\#204) are highlighted in red. (**e**) Tracks showing the irCLIP-seq signal across the A-repeats of *Xist*. Tracks are shown for Spen KO +RRM2-4 (+ / - *Xist*), Spen full-length, and V6.5 male mESCs. irCLIP-seq clusters are shown in black at the top. (**f**) Tracks showing the irCLIP-seq signal across exon 2 of *Spen*. Tracks are shown for Spen KO +RRM2-4 (+ / - *Xist*), Spen full-length, and an IgG control. irCLIP-seq clusters are shown in black at the top. (**g**) Graph showing the number of bound TE loci for each TE subfamily with significant Spen RRM2-4 binding. (**h**) Graph showing the percentage of TE loci bound for each TE subfamily with significant Spen RRM2-4 binding. (**i**) Expression of RRM-bound LTRs in WT mESCs (green) and *Spen* KO mESCs (orange). Shown is the log~2~ transformed normalized RNA-seq read counts. For all boxplots, the thick line represents the median, while the box gives the IQR. *P* values are calculated using a two-tailed T test. (**j**) Same as in i for RRM-bound ERVKs. (**k**) Same as in i for RRM-bound MMETns.](elife-54508-fig3){#fig3}

To test this, we performed infrared crosslinking immunoprecipitation followed by sequencing (irCLIP-seq), which allows for identification of direct RBP binding sites on RNA ([@bib57]). Because of Spen's large size (\~400 kDa) and the lack of highly specific antibodies to it ([Figure 3---figure supplement 1a,b](#fig3s1){ref-type="fig"}), we expressed a FLAG-tagged version of the Spen RNA binding domains (RRM2-4) for irCLIP-seq. We also compared irCLIP-seq data performed using an antibody against the endogenous, full-length Spen protein, despite the higher level of non-specific signal in those experiments ([Figure 3---figure supplement 1a,b](#fig3s1){ref-type="fig"}; [@bib32]). RRMs 2--4 were shown to be bona fide RNA binding domains, with RRM3 specifically required for binding to known Spen binding partner *SRA* RNA in vitro ([@bib1]). We expressed tagged Spen RRM2-4 in both *Spen* KO mESCs, which express *Xist* upon doxycycline treatment, and in WT male V6.5 mESCs, which do not express *Xist*, but do express *ERVs*. Following UV crosslinking of RNA and protein complexes in vivo, we isolated RRM2-4-bound RNAs using an anti-FLAG antibody and prepared libraries from the isolated RNA.

On mRNAs and lncRNAs, we detected Spen RRM2-4 binding at 29,625 sites (irCLIP-seq clusters), on a total of 4732 transcripts ([Figure 3b,c](#fig3){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Compared to other RBPs, Spen binds relatively very few RNAs in irCLIP-seq ([Figure 3d](#fig3){ref-type="fig"}). *Xist* was the top bound gene, with much higher binding strength than other RNAs, consistent with its known interaction with the A-repeat region of *Xist* and role in XCI ([@bib7]; [@bib36]; [@bib37]; [@bib40]; [@bib39]; [@bib10]; [@bib41]; [Figure 3d](#fig3){ref-type="fig"}). Spen RRM2-4 binds specifically to the A-repeat monomers as reported for full-length and truncated Spen ([Figure 3e](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1c](#fig3s1){ref-type="fig"}; [@bib31]; [@bib32]; [@bib1]). This confirmed that our FLAG-tagged RRMs bind Spen's RNA targets in vivo. In addition to *Xist*, Spen binds to several mRNAs, one of which is the *Spen* mRNA itself ([Figure 3d,f](#fig3){ref-type="fig"}). This is consistent with our observation that loss of Spen protein leads to upregulation of *Spen* mRNA expression, suggesting that the Spen protein represses its own RNA output in *cis*.

To assess whether Spen RRM2-4 binds directly to ERVK-derived RNA, we mapped irCLIP-seq data to TEs in the genome. Because irCLIP-seq reads are short and single ended and thus less likely to map uniquely to these repetitive elements, we mapped reads only to the elements that are expressed in our RNA-seq data. We detected a total of 7812 irCLIP-seq clusters on TE RNAs (20% of total clusters detected), covering 2267 individual TEs ([Figure 3b,c](#fig3){ref-type="fig"}). Of these, we detected RRM2-4 binding at 442 LTRs and 208 ERVKs. The TE subfamily with the greatest number of bound elements is the MMETn-int family, a member of the ETn class ([Figure 3g,h](#fig3){ref-type="fig"}). In addition, RLTR13G and ETnERV-int showed a large number of elements bound as well as a high percentage of total genomic elements bound ([Figure 3g,h](#fig3){ref-type="fig"}). RRM-bound elements within these families show modestly increased RNA expression in Spen KO mESCs, consistent with Spen binding contributing to repression of these sites ([Figure 3i--k](#fig3){ref-type="fig"}). These *ERV* RNAs are bound by RRM2-4 as well as full-length Spen ([Figure 3---figure supplement 1d--f](#fig3s1){ref-type="fig"}; [Figure 3---figure supplement 2a,b](#fig3s2){ref-type="fig"}).

The specificity of RBP binding to its RNA targets may have a structural and/or sequence basis. In order to understand whether Spen binds to the A-Repeat and *ERV* RNAs in the same manner, we first investigated the sequence features in Spen-bound mRNAs, lncRNAs, and ERVs. We found that RRM2-4 binding sites on mRNA and lncRNAs, as well as ERVs, are enriched for AU content, but did not find any longer, more complex motifs shared amongst the classes. Furthermore, we did not find sequences that showed strong homology to the highly conserved A-Repeat regions ([Figure 3---figure supplement 3a--c](#fig3s3){ref-type="fig"}). This was perhaps not surprising, as [@bib1] previously showed that Spen's recognition of the *SRA* lncRNA is largely dictated by RNA secondary structure, not sequence, with Spen binding to a flexible, single stranded region adjacent to a double stranded region.

We asked whether Spen RRMs bind to a similar structural feature in the A-Repeat and in *ERV* RNAs. Spen has previously been reported to bind to the junction between a single stranded loop and a duplex formed by multiple A-Repeat monomers interacting in three dimensions ([@bib31]), a structure that is similar to Spen's binding site within SRA ([@bib1]). Upon closer examination of icSHAPE data, which determines whether RNAs are single (high icSHAPE reactivity score) or double stranded (low icSHAPE reactivity score) in vivo ([@bib48]), we found that the A Repeat region of *Xist* consists of a hairpin that contains a small bulging single stranded region, flanked by two larger single stranded loops ([Figure 4a--e](#fig4){ref-type="fig"}). Both the Spen RRMs and the full length Spen bind to the conserved single stranded regions directly adjacent to the double-stranded hairpin and to the small bulge within the hairpin ([Figure 4a--e](#fig4){ref-type="fig"}).

![Spen RRMs recognize a common structural feature in A-Repeat and *ERV* RNA.\
(**a**) irCLIP-seq signal from full-length Spen ([@bib21]) across the 8 *Xist* A-repeats. Signal for each repeat is stacked across the conserved repeat region. (**b**) Same as in a for RRM2-4 irCLIP-seq. (**c**) icSHAPE reactivity scores for each of the *Xist* A-repeats performed in vitro. Signal for each repeat is stacked across the conserved repeat region. (**d**) Phylo-P scores across the A-repeats, showing conservation of repeat sequence at the RRM2-4 binding sites. (**e**) Structural model for Xist A-repeats 4 and 5 which form a hairpin structure. Structural prediction is supported by icSHAPE data. At each nucleotide, the RRM2-4 irCLIP-seq signal strength is plotted as a bar for each repeat (in color). (**f**) irCLIP-seq signal (top, black) and icSHAPE reactivity scores (bottom, gray) for the consensus sequence of RLTR13G elements. Included are elements for which we have both confident RRM2-4 binding and icSHAPE data. (**g**) Same as in f for ETnERV. (**h**) Same as in f for MMETn-int. (**i**) Structural model for ETnERV. Structural prediction is supported by icSHAPE data. At each nucleotide, the RRM2-4 irCLIP-seq signal strength is plotted as a bar.](elife-54508-fig4){#fig4}

To test whether Spen RRMs bind a similar structural motif in *ERVK* RNAs, we analyzed icSHAPE data within repeat regions of the genome ([@bib49]). For LTR families for which we had enough loci that are both bound by RRMs and have icSHAPE signal, (RLTR13G, ETnERV, MMETn) we found that Spen binding occurs within short single stranded regions adjacent to double stranded regions ([Figure 4f--h](#fig4){ref-type="fig"}). This is consistent with a model where Spen RRMs bind to single-stranded bulges within larger duplexes in *ERVK* RNAs ([Figure 4i](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1a,b](#fig4s1){ref-type="fig"}). Taken together, this demonstrates that Spen RRMs bind to the A-repeat of *Xist* and to *ERVK* RNAs in the same manner, recognizing a specific structural feature in the RNA.

Though irCLIP-seq provides a transcriptome-wide map of Spen RRM-RNA binding, we wanted to understand in even more depth the specificity and strength of the interaction between the Spen RRMs and *ERVK* RNAs. We hypothesized that if Spen binds *ERVK*s and the A-Repeat with the same structural recognition mechanism, it should bind with similar affinity and in a competitive manner. We used fluorescence anisotropy experiments to measure the binding affinity of Spen RRMs 2--4 to *ERV* RNA elements as well as the *Xist* A-repeat and the *SRA* RNA H12H13 hairpin, two known interactors of Spen ([@bib7]; [@bib36]; [@bib31]; [@bib1]). We also measured binding of a version of the Spen RRMs that has five point mutations in RRM3 (RRM3 Mt), which was previously shown to diminish binding of Spen to SRA ([Figure 4---figure supplement 2a](#fig4s2){ref-type="fig"}; [@bib1]). Using in vitro irCLIP RNA isolation, we found that the RRM3 Mt binds \~50% less RNA than RRM2-4 confirming these residues are essential for Spen RNA binding ([Figure 4---figure supplement 2b--f](#fig4s2){ref-type="fig"}).

Using fluorescence anisotropy, we found that the binding affinity of Spen RRM2-4 for our *ERV* transcripts and the *Xist* A-Repeat are similar (dissociation constant *K~D~* = 53 nM\~140 nM), and higher than the affinity of Spen RRM2-4 for the *SRA* hairpin (K~D~ = 450 nM) ([Figure 5a,b](#fig5){ref-type="fig"}). The binding affinity of the RRM3 Mt is about half that of the RRM2-4 for both *Xist* A-repeat and the *ERV* RNAs, suggesting that the same residues of Spen's RRM3 domain are binding both *Xist* A-repeat and *ERV* RNAs ([Figure 5b](#fig5){ref-type="fig"}; [Figure 4---figure supplement 2g](#fig4s2){ref-type="fig"}). Finally, we found that an unlabeled *ERV* RNA competed with a labeled *Xist* A-repeat for binding to Spen RRM2-4, further demonstrating that Spen recognizes these two RNAs, in part, through the same binding domain and in a very similar manner ([Figure 5c](#fig5){ref-type="fig"}). These data, taken with our irCLIP-seq data, show that Spen binds to ERVK-derived RNA in the nucleus and does so via the same binding mechanism and with the same strength as it binds the A-Repeat of *Xist*. This supports a model in which Spen directly represses ERVK loci in the genome by recognizing their RNA transcripts through their secondary structures.

![ERVs bind Spen RRMs in vitro and compete with the A-Repeat.\
(**a**) Representative binding curves for Spen RRM2-4 from fluorescence anisotropy experiments. Fluoresence anisotropy values are normalized with saturation and offset parameters from the fit to yield fraction bound. Shown are binding curves for *SRA*, the A-Repeat region of *Xist* (A rep), and two *ERV* RNAs bound in irCLIP-seq data (ERV509, ERV411). (**b**) Direct binding constants (K~D~) between RNAs of interest and the Spen RRM2-4 and RRM3 Mt proteins from fluorescence anisotropy experiments. Error is the standard error. The fold change in binding between RRM2-4 and RRM3 Mt for each RNA is shown at the right. (**c**) Acrylamide gel image showing competition of ERV509 RNA with ^32^P-labeled A-Repeat for binding to Spen RRM2-4. Increasing amounts of unlabeled ERV509 competitor RNA (0.5x, 1x, 5x, and 10x the amount of labeled A-Repeat) was added while the protein and A-Repeat concentrations were kept constant. The higher band depicts Spen-bound A-Repeat, while the lower band shows the unbound A-repeat RNA.](elife-54508-fig5){#fig5}

Collectively, these results show that Spen's RNA binding domains bind TE-derived RNA in mESCs and do so via the same mechanism that they bind *Xist* RNA, with a significant contribution from the RRM3 domain. The observation that the A-repeat may be derived from an ancient ERV insertion ([@bib12]), which shows structural similarity to the ERV elements bound by Spen, suggests that *Xist* evolved its ability to recruit Spen via Spen's recognition of ERV sequence and subsequent recruitment of repressive complexes. Spen itself has evolved relatively little throughout evolution from fish to humans, and Spen's RNA binding domains show no evidence of branch-specific evolution in the eutherian clade ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Thus a mechanism in which the *Xist* RNA itself evolved toward Spen's functionality is fitting.

We reasoned that if the *Xist* A-repeat region evolved via the insertion of a TE that had affinity for Spen into the proto-*Xist* locus, then the insertion of an ERV element into *Xist* may be able to complement the A-repeat deletion of *Xist*. We would expect that this chimeric *Xist-ERV* would be able to 1) recruit and bind to Spen and 2) silence X-linked genes in cis ([Figure 6a](#fig6){ref-type="fig"}). To test this hypothesis, we utilized a male (XY) mESC line that harbors both a doxycycline inducible *Xist* gene on the X as well as a deletion of the A-repeat region (Xist-ΔA) ([@bib54]). While induction of *Xist* by doxycycline treatment in the WT male mESCs (Xist-WT) leads to silencing of the single X chromosome, *Xist* expression in Xist-ΔA mESCs has no effect on X chromosome gene expression or accessibility ([@bib54]; [@bib15]). We used CRISPR-Cas9 genome editing to insert a 9x array of a 154 bp ERV-derived Spen binding site from chromosome 16 into the X chromosome where the A-repeat has been deleted in Xist-ΔA mESCs (Xist-ERV) ([Figure 6---figure supplement 2a--c](#fig6s2){ref-type="fig"}). We chose a 9x array of binding sites because the A-repeat region of *Xist* consists of 8.5 repeats in human and 7.5 repeats in mouse, which fold into a complex secondary structure with multiple Spen binding sites ([@bib31]; [@bib38]). Furthermore, the addition of monomers of the A-repeat up to nine repeats in an A-repeat knockout background leads to a linear increase in chromosome silencing capacity ([@bib54]; [@bib38]).

![Insertion of an ERV element in place of A-repeat restores Spen binding and local Xist silencing.\
(**a**) Diagram showing the experimental rationale for replacing the A-Repeat with a 9x tandem insert of an ERV-derived Spen binding site. (**b**) *Xist-ERV* restores Spen recruitment. RIP-qPCR for *Xist* and *ActB* in Xist-WT, Xist-ΔA, and Xist-ERV clones 1 and 2 mESCs. qRT-PCR values are normalized to input samples. Error bars represent standard error for four independent biological replicates. p values are derived from two-tailed *t*-test. (**c**) Xist-ERV causes epigenetic silencing of the *Xist* locus. *Xist* expression level in +Dox compared to --Dox conditions for Xist-ΔA mESCs and Xist-ERV mESCs with and without HDAC1/2 inhibitor treatment. *Xist* levels are first normalized to *ActB* and then to --Dox levels. The red line is drawn at y = 0, representing no increase in expression of *Xist* with the addition of doxycycline. For each condition, four independent experiments were conducted. p values are derived from two-tailed T test. (**d**) Xist-ERV silencing requires Spen and HDAC3. *Xist* expression level in +Dox compared to --Dox conditions for Xist-ΔA mESCs and Xist-ERV mESCs with and without siRNA-mediated knockdown of Spen or siRNA-mediated knockdown of Spen + HDAC3 inhibition. For each condition, four independent experiments were conducted. (**e**) Model for how Spen evolved to bind *Xist* through its *ERV* binding mechanism in eutherian mammals.](elife-54508-fig6){#fig6}

We first asked whether *Xist-ERV* is able to bind directly to and recruit Spen. To do this, we expressed the FLAG-tagged Spen RRM2-4 in our cell lines containing Xist-WT, Xist-ΔA, or Xist-ERV transgenes (two independent clones), and measured *Xist*-RRM binding under optimized expression conditions (more below), by RIP-qPCR. We found that *Xist-ERV* is bound by Spen RRM2-4, similar to *Xist-WT* and in contrast to *Xist-ΔA* which could not bind Spen ([Figure 6b](#fig6){ref-type="fig"}). Next, when we quantified the ability to induce *Xist-ERV* expression with the addition of doxycycline, we were surprised to find that expression of *Xist-ERV* could not be induced, in comparison to *Xist-WT* and *Xist-ΔA* ([Figure 6c](#fig6){ref-type="fig"}). Genetic analysis confirmed that the Tet operator and CMV promoter were intact in all of our *Xist-ERV* clones ([Figure 6---figure supplement 2d](#fig6s2){ref-type="fig"}), suggesting that the lack of gene induction may be due to epigenetic silencing recruited by Spen. To test whether the inability to induce *Xist-ERV* expression was due to silencing in cis, we treated cells with an HDAC1/2 inhibitor (HDAC1/2i) or an HDAC3 inhibitor (HDAC3i) for 24 hr before *Xist* induction. We found that both HDAC1/2i and HDAC3i de-repressed the transgene and *Xist-ERV* was expressed ([Figure 6c](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2e--h](#fig6s2){ref-type="fig"}).

To test whether this *Xist-ERV* silencing was Spen-dependent, we used siRNAs to knockdown Spen 24 hr prior to induction of *Xist* with doxycycline. We found that *Xist-ERV* expression was elevated in Xist-ERV clones 1 and 2 after Spen knockdown ([Figure 6d](#fig6){ref-type="fig"}). The rescue of *Xist-ERV* expression by Spen depletion was quite variable from experiment to experiment; addition of an inhibitor of HDAC3, which is recruited by Spen ([@bib59]; [@bib36]), made the Xist-ERV induction substantially more consistent and up to 20-fold in at least one clone ([Figure 6d](#fig6){ref-type="fig"}). This suggested that *Xist-ERV* recruits Spen, leading to local silencing of the *Xist* transgene in cis.

Therefore, the insertion of an ERV-derived RNA motif into *Xist* is sufficient to partially substitute for the A-repeat, recruit Spen to the chimeric RNA, and mediate strictly local gene silencing in cis. This is the first demonstration of how a TE insertion during evolution could confer new functionality on a noncoding RNA, by introducing a new protein recruitment domain ([@bib20]).

Finally, we tested whether this Spen recruitment by the *Xist-ERV* RNA is sufficient to lead to chromosome-wide silencing. We conducted these experiments in the presence of HDAC1/2 inhibition, which increases *Xist* induction but was previously shown not to affect silencing during XCI ([@bib59]). While expression of X-linked genes *Pgk1*, *Gpc4*, *Mecp2*, and *Rnf12* was reduced after *Xist* induction in Xist-WT cells, expression was unchanged upon expression of *Xist-ΔA* or *Xist-ERV* ([Figure 6---figure supplement 3a](#fig6s3){ref-type="fig"}). Thus, while the addition of the ETn array to an A-repeat-deficient *Xist* was sufficient to recruit Spen, it was not sufficient to carry out XCI. These experiments were conducted in the presence of HDAC1/2i, necessary to overcome Xist-ERV silencing of its own locus, but may also inhibit the chimeric RNA's silencing of distal loci. Furthermore, this could be due to the differences in levels of *Xist* that we are able to induce in this system, which are lower in the Xist-ERV cells than the Xist WT or Xist ΔA cells, even in the presence of HDAC1/2i. Nevertheless, our results are consistent with the hypothesis that insertion of an ERV element into the proto-*Xist* locus was an *early* evolutionary step in the functionalization of the A-repeat, but that additional rounds of evolution may have subsequently acted on this region of the genome in order to evolve *Xist*'s full functionality for silencing the entire chromosome over long genomic distance ([@bib12]; [@bib5]).

Discussion {#s3}
==========

Here we show that Spen, a highly conserved and pleiotropic RNA binding protein, binds to and regulates specific classes of ERVK loci in mouse embryonic stem cells. Spen represses these ERVK loci via a direct mechanism where it binds transcripts derived from these parasitic elements, and can then recruit its chromatin silencing protein partners. In the absence of Spen, these elements become derepressed, showing loss of repressive H3K9me3 and gain of active chromatin modifications. Sensing transposon silencing at the RNA level is attractive, as it provides a mechanism for the cell to identify the 'leaky' locus and target the silencing machinery to the locus in *cis*.

These observations are striking when taken with the observation that the *Xist* RNA, which is also robustly bound by Spen, is derived from a number of ancient retroviral insertions ([@bib12]). We show direct evidence, for the first time, that an *Xist* binding protein can bind to ERV-derived RNA in vivo, and thus may have been recruited to *Xist* via the insertion of an ERV element into the proto-*Xist* locus ([Figure 6e](#fig6){ref-type="fig"}). This evidence supports the hypothesis that lncRNAs, which are evolutionarily young, may exapt TE-protein interactions in order to form functional protein binding domains ([@bib20]; [@bib23]; [@bib17]; [@bib19]). In effect, *Xist* lncRNA 'tricks' the female cell to perceive the inactive X chromosome as being coated by dangerous transposon RNAs. The cell can then deploy Spen, a transposon-silencing protein, to carry out X chromosome dosage compensation.

One of the major mysteries of X inactivation is the *cis*-restriction of *Xist*, which only silences the chromosome from which it is expressed, a property critical for dosage compensation of two X chromosomes in females to one X in males. Our discovery of the link between Spen and transposon silencing suggests an ancient evolutionary origin for *cis* silencing. Spen sensing of *ERV* RNA and Spen-mediated silencing are *cis* restricted, and indeed grafting ERV into the *Xist* locus caused *cis* silencing of *Xist* RNA expression itself. Hence, these data suggest that the invasion of an ERV-like sequence into proto-*Xist* led first to RNA-based silencing in *cis*. Subsequent mutations in this proto-*Xist* may then have allowed this RNA to localize to and silence distal sites on the X chromosome. The transition from short to long range silencing in *cis* may be a fruitful topic in future studies.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                          Source or reference   Identifiers                                                                                                                                   Additional information
  (species) or resource                                                                                                                                                                                                              
  ------------------------- ------------------------------------ --------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Gene (mouse)              Spen                                 RefSeq                [NM_019763.2](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=Nucleotide&term=NM_019763&doptcmdl=GenBank&tool=genome.ucsc.edu)   

  Cell line (mouse)         TXY WT and TXY deltaA                Dr. Edith Heard       Xist-WT and Xist-deltaA                                                                                                                       Cell lines have a doxycycline inducible Xist gene + / - the A repeat region

  Cell line (mouse)         HATX WT and HATX Spen KO             Dr. Anton Wutz        WT, *Spen* KO                                                                                                                                 KO cells have a deletion\
                                                                                                                                                                                                                                     of the majority of the Spen gene. They also have a doxycycline inducible Xist transgene on the X chromosome

  Antibody                  Goat polyclonal\                     Santa Cruz            Sc-8629                                                                                                                                       7.5 ug/ChIP
                            Anti-Oct4                                                                                                                                                                                                

  Antibody                  Rabbit polyclonal\                   Active Motif          39133                                                                                                                                         5 ug/ChIP
                            Anti-H3K27Ac                                                                                                                                                                                             

  Antibody                  Rabbit polyclonal Anti-SHARP(Spen)   Bethyl                A301-119A                                                                                                                                     Antibody to endogenous Spen

  Antibody                  Mouse monoclonal Anti-FLAG M2        Sigma                 F3165                                                                                                                                         Antibody against FLAG tag on Spen RRM2-4

  Antibody                  Rabbit polyclonal Anti-H3K9me3       abcam                 AB8898                                                                                                                                        5 ug/ChIP

  Antibody                  Rabbit polyclonal Anti-H3K4me3       Active Motif          39159                                                                                                                                         5 ug/ChIP

  Sequence-baed reagent     mXist 570 RNA FISH probe set         Stellaris             SMF-3011--1                                                                                                                                   125 nM concentration

  Commercial assay or kit   Nextera DNA prep kit                 Illumina              FC-131--1002                                                                                                                                  Used for ATAC-seq and for ChIP-seq library preparation.

  Chemical compound, drug   HDAC1/2 inhibitor, BRD6688           Cayman Chemical       1404562-17-9                                                                                                                                  Inhibitor of\
                                                                                                                                                                                                                                     HDAC1 and 2. Used at 10 uM.

  Chemical compound, drug   HDAC3 inhibitor, RGFP966             Sigma                 SML1652                                                                                                                                       Inhibitor of HDAC3. Used at 10 uM.

  Sequence-based reagent    Xist Primers                         Dr. Edith Heard       5'GCTGGTTCGTCTATCTTGTGGG3'\                                                                                                                   
                                                                                       5'CAGAGTAGCGAGGACTTGAAGAG3'                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines and culture {#s4-1}
----------------------

HATX WT and Spen KO clone 2 and clone 3 cell lines were gift of A. Wutz and are described in detail in [@bib40]. TXY WT (Xist-WT) and TXY deltaA (Xist-ΔA) cell lines were gift of E. Heard. mESCs were cultured in serum/LIF conditions (Knockout DMEM (GIBCO 10829018), 1% Penicillin/streptomycin, 1% GlutaMax, 1%non-essential amino acids, beta-mercaptoethanol, Hyclone fetal bovine serum (Fisher SH3007103), and 0.01% LIF (ESGRO ESG1107). Cells were cultured on 0.2% gelatin-covered plates and passaged every 2--3 days with trypsin as needed. All cell lines tested negative for mycoplasma.

*Xist* induction {#s4-2}
----------------

For *Xist* induction experiments, mESCs were plated at a density of 75,000 cells/well in a 6-well plate. 24 hr after plating, cells were treated with 2 ug/mL doxycycline for 48 hr (unless shorter or longer time is indicated in figure legend). Induction of *Xist* was confirmed using qPCR and *Xist* RNA FISH. qPCR primers used for Xist have the following sequences: Forward 5'GCTGGTTCGTCTATCTTGTGGG3' and Reverse 5'CAGAGTAGCGAGGACTTGAAGAG3'.

HDAC inhibition experiments {#s4-3}
---------------------------

For HDAC inhibition experiments, cells were treated with either HDAC1/2i (BRD6688, Cayman Chemical Company, 1404562-17-9) or HDAC3i (RGFP966, Sigma SML1652) at 10 uM final concentration. HDAC inhibition was initiated 24 hr prior to induction of *Xist* with doxycycline and continued for 24 hr during *Xist* induction (48 hr total). --HDACi samples were treated with DMSO as a control.

*Xist* RNA FISH {#s4-4}
---------------

Following *Xist* induction, adherent cells on coverslips were fixed using 4% paraformaldehyde for 10 min. Cells were permeablized in 0.5% triton for 10 min on ice and then stored in 70% EtOH. After dehydration in EtOH, cells were rehydrated in wash buffer (2xSSC + 10% formamide) for 5 min. Probe (Stellaris mXist 570, SMF-3011--1) was then added at a concentration of 125 nM (in wash buffer + 10% Dextran Sulfate) and incubated overnight at 37'C. Following washes in wash buffer + formamide, coverslips were mounted on slides with Vectashield + DAPI.

NPC differentiation {#s4-5}
-------------------

NPC differentiation from mESCs was performed as previously described ([@bib8]). Briefly, mESCs were plated on gelatin-coated plates in N2B27 medium for 7 days. On day 7, cells were dissociated with Accutase and cultured in suspension in N2B27 medium with FGF and EGF (10 ng/ml, each). On day 10, embryoid bodies were plated onto 0.2% gelatin-coated plates and allowed to grow until 14 days. At 14 days, cells were stained with anti-Nestin (Millipore, MAB353) antibody to confirm NPC identity. For qRT-PCR RNA was extracted from Trizol using the RNEasy Mini kit (Qiagen). RNA was then used directly for qRT-PCR using the following primers. Oct4-F: 5' TTGGGCTAGAGAAGGATGTGGTT3', Oct4-R: 5' GGAAAAGGGACTGAGTAGAGTGTGG3' ActB-F: 5'TCCTAGCACCATGAAGATCAAGATC3', ActB-R: 5'CTGCTTGCTGATCCACATCTG3'.

Immunofluorescence {#s4-6}
------------------

Immunofluorescence for Oct4 and Nestin was performed on adherent cells fixed with 4% paraformaldehyde. After fixation, cells were permeablized with 0.5% PBS/Triton for 10 min on ice. Following permeablization, cells were blocked in 10% FBS in 0.1% PBS/Tween for 1 hr at room temperature. After blocking, cells were incubated for 2 hr in primary antibody (Nestin: Millipore, MAB353, Oct4: Santa Cruz sc-8629), washed in 0.1% PBS/Tween and then incubated for 2 hr in secondary antibody (Goat anti-mouse 488 Life Technologies ab150113, Rabbit anti-goat 488 Life Technologies A27012). After washing, cells were stained with DAPI and imaged at 40x magnification.

Chromatin immunoprecipitation {#s4-7}
-----------------------------

Cells were fixed with 1% formaldehyde for 10 min at room temperature and subsequently quenched with 0.125M glycine. Cells were then snap frozen and stored at −80'C. Cells were then lysed (50 mM HEPES-KOH, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100) for 10 min at 4'C. Nuclei were lysed (100 mM Tris pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) for 10 min at room temperature. Chromatin was resuspended in sonication buffer (10 mM Tris pH 8.0, 1 mM EDTA, 0.1% SDS) and sonicated using a Covaris Ultrasonicator to an average length of 220 bp. For all ChIPs, 5 million cells per replicate were incubated with 5 ug (Histone) or 7.5 ug (Oct4) antibody overnight at 4'C (antibodies: H3K9me3: abcam AB8898; H3K27Ac: Active Motif 39133; H3K4me3: Active Motif 39159; Oct4: Santa Cruz sc-8629). Antibody-bound chromatin was incubated with Protein G Dynabeads (Invitrogen, 10004D) for 4 hr at 4'C and eluted in Tris buffer (10 mM Tris pH 8.0, 10 mM EDTA, 1% SDS). Crosslinks were reversed by incubation overnight at 65'C followed by treatment with 0.2 mg/mL proteinase K (Life Technologies, AM2548) and 0.2 mg/mL RNAse A (Qiagen). DNA was purified using Qiagen Minelute Columns (Qiagen, 28006). For library preparation, 4 ng ChIP DNA was incubated with transposase (Illumina, Fc-121--1030) for 10' at 55'C. DNA was then amplified using Nextera barcoding adapters and sequenced on an Illumina Nextseq (2 × 75 bp reads).

ChIP-seq analysis {#s4-8}
-----------------

ChIP-seq libraries for histone modifications were sequenced on an Illumina NextSeq with paired-end 75 bp reads. Reads were mapped to the mm9 genome build using Bowtie2 ([@bib26]). Unique and coordinated mapped paired reads were kept and duplicate reads were then removed using Picard Tools.

Peaks were called using MACS2 with a q-value cutoff of 0.01 with input as background ([@bib58]). Peaks called from two technical replicates were compared by IDR package and further filtered by the Irreproducible Discovery Rate(\<0.05) ([@bib27]). Reproducible peaks from WT and KO conditions were merged and reads in these peaks were counted across all libraries. Differential peaks were called using reads counts from reproducible peaks with DESeq2(fold change \>= 2 and Padjust \<0.01) ([@bib30]). Bigwig files were generated from deduplicated bam files using bedtools for visualization ([@bib42]).

ATAC-seq {#s4-9}
--------

ATAC-seq library preparation was performed exactly as described in [@bib6]. Briefly, ESCs were dissociated using Accutase (SCR005,Millipore). 50,000 cells per replicate (two replicates per clone) were incubated with 0.1% NP-40 to isolate nuclei. Nuclei were then transposed for 30' at 37'C with adapter-loaded Nextera Tn5 (Illumina, Fc-121--1030). Transposed fragments were directly PCR amplified and sequenced on an Illumina NextSeq 500 to generate 2 × 75 bp paired-end reads.

ATAC-seq analysis {#s4-10}
-----------------

Reads were trimmed using CutAdapt ([@bib35]) and mapped to the mm9 genome build using Bowtie2 ([@bib26]). Unique and coordinated mapped paired reads were kept and duplicate reads were then removed using Picard Tools. Peaks were called using MACS2 with a q-value cutoff of 0.01 and no shifting model ([@bib58]). Peaks called from two technical replicates were compared by IDR package and further filtered by the Irreproducible Discovery Rate(\<0.05) ([@bib27]). Reproducible peaks from WT and KO conditions were merged and reads in these peaks were counted across all libraries. Differential peaks were called using reads counts from reproducible peaks with DESeq2(fold change \>= 2 and P-adjusted \<0.01) ([@bib30]). To calculate *P* values in DESEq2, for each gene the counts were modelled using a generalized linear model (GLM) of negative binomial distribution among samples. The two-sided Wald statistics test was processed for significance of the GLM coefficients. The Benjamini-Hochberg correction was applied to all p-values to account for multiple tests performed. This gives the final adjusted p-values used for assessing significance.

ATAC-seq analysis for X chromosome silencing {#s4-11}
--------------------------------------------

ATAC-seq reads were trimmed and mapped as described above. Peaks were called in all samples (+ and -- doxycycline) and bedtools multicov was used to count the number of reads falling within each peak in each sample. In order to avoid bias in normalization in the case of a global loss of accessibility on the X chromosome, we first normalized count data using all peaks genome-wide. We then calculated the ratio of average normalized reads in +dox / -dox samples at each peak on the X chromosome.

RNA-seq {#s4-12}
-------

RNA-seq library preparation was performed using the TruSeq Stranded mRNA Library Prep Kit (Illumina, RS-122--2102). In place of poly-A selection, we performed Ribosomal RNA depletion using the RiboMinus Eukaryote System v2 (Life Tech. A15026). Each library was prepared from 200 ng starting RNA, and two replicates were made for each cell line. RNA-seq libraries were sequenced on an Illumina HiSeq 4000 with paired 2 × 75 bp reads.

RNA-seq analysis {#s4-13}
----------------

RNA-seq reads were mapped to the mm9 genome using STAR ([@bib9]). Following read alignment, reads were assigned to transcripts using FeatureCounts in R (RSubread) ([@bib28]). GTF file from gencode was used for feature assignment (<https://www.gencodegenes.org/mouse_releases/1.html>). Differential genes were called using DESeq2 (fold change \>= 2, P-adjusted \<0.001) ([@bib30]). For GO term analysis of RNA-seq data, GOrilla was used ([@bib11]).

Enrichment of genomic loci in ATAC-seq and ChIP-seq data {#s4-14}
--------------------------------------------------------

HOMER was used for enrichment of genomic locations in ATAC-seq and ChIP-seq data ([@bib18]). Specifically, we used the annotatePeaks.pl script with the --genomeOntology option.

In vivo irCLIP-seq {#s4-15}
------------------

For in vivo irCLIP-seq experiments, V6.5 male mESCs, or *Spen* KO Clone 2 mESCs were transduced with a lentivirus carrying Spen RRMs 2--4 with the SV40 nuclear localization signal, 2x HA tags, and 3x FLAG tag ('SpenRRM-FLAG'; pLVX-EF1a-SV40NLS-SpenRRM234-2xHA-3xFLAG-IRES-zsGreen). Following transduction, GFP+ cells were FACS sorted and single colonies were picked. Western blotting was used to confirm the expression of SpenRRM-FLAG at 37 kDa. irCLIP was performed exactly as described ([@bib57]). Briefly, 2 million mESCs were UV-crosslinked (254 nM UV-C) at 0.3 J/cm^2^, and then lysed (1% SDS, 50 mM Tris pH7.5, 500 mM NaCl) and sonicated using a Bioruptor (Diagenode) (six cycles 30' on 45' off). Clarified lysates were incubated overnight with Protein A dynabeads conjugated to mouse anti-FLAG (Sigma Aldrich F3165) or anti-IgG antibody overnight at 4C. Following IP, beads were washed in high stringency buffer (15 mM Tris-HCl, pH 7.5; 5 mM EDTA; 1% Triton X-100; 1% Na-deoxycholate; 0.001% SDS; 120 mM NaCl; 25 mM KCl), high salt buffer (15 mM Tris-HCl, pH 7.5; 5 mM EDTA; 1 mM Triton X-100; 1% Na-deoxycholate; 0.001% SDS; 1000 mM NaCl), and low salt buffer (15 mM Trish-HCl, pH 7.5; 5 mM EDTA). After washing, RNA was digested using RNase I at 1:2000. RNA ends were then dephosphorylated and IR-conjugated linker (/5Phos/AGATCGGAAGAGCGGTTCAGAAAAAAAAAAAA/iAzideN/AAAAAAAAAAAA/3Bio/) was ligated overnight. Following ligation, samples were run on a 4--12% Bis-Tris gel, transferred to nitrocellulose and imaged using an Odyssey LiCOR scanner. RNA-protein complexes were eluted from nitrocellulose and treated with proteinase K to eliminate protein. Following RNA elution, Oligo(dT) Dynabeads were added to capture the polyadenylated irCLIP adapter. Next, the TruAmp sequencing adapter was added and RNA was reverse transcribed using SuperScript IV. Following reverse transcription, DNA was captured with streptavidin beads, circularized on the bead, and then PCR amplified. irCLIP libraries were then purified using PAGE gel purification and sequenced on an Illumina NextSeq using single-end 75 bp reads.

Expression and purification of wild-type and mutant spen RRMs 2--4 for in vitro irCLIP RNA binding {#s4-16}
--------------------------------------------------------------------------------------------------

The following constructs for SPEN (Split Ends protein), SHARP (human homolog, SMRT/HDAC1 Associated Repressor Protein), were designed and cloned into pET28a for *E. coli* expression.

1.  SPEN-1=6 His-GST-TEV- RRM 2,3,4-SG-Flag

2.  SPEN-4=6 His-GST-TEV- RRM 2,3,4-RRM3mutant-SG-Flag

DNA for each was transformed into BL21 (DE3) Star competent cells, the transformation mix plated on LB-Kan agar and single colonies obtained the following day. 4 × 50 ml overnight pre-cultures were setup with single colonies for each construct in Terrific Broth (Teknova) + Kanamycin (50 ug/ml) (TB-Kan), at 37C, 250 rpm. Pre-cultures were used to inoculate 1li volumes of TB-Kan expression media at 10 ml/li (gives a starting OD600 = 0.15). Expression cultures were incubated at 37C, shaken at 250 rpm, for 4 hr then chilled to 18C for 1 hr and induced overnight with 0.25 mM IPTG at 18C. Cultures were harvested and resulting cell pellets were stored frozen at −80C. Frozen cell pellets were resuspended in 5 ml/g of Lysis Buffer(50 mM HEPES;pH 7.5, 300 mM NaCl, 20 mM Imidazole, 0.1% Triton X-100, DNase I (1 ug/ml), Lysozyme (1 ug/ml), 5 mM 2-ME, 2 x Roche protease Inhibitor tablet/50 ml and 1 mM PMSF). Resuspended pellets (in suspensions) were homogenized by Polytron and lysed by two rounds through a Microfluidizer (18000 psi). Lysates were clarified by centrifugation at 33000 x g for 60mins, the supernatant extracted and subjected to batch binding with 5 ml of NiNTA (Qiagen) for 2 hr, 4C with end-to-end rotation. Resin was washed with 20Cv's of Lysis Buffer containing 20 mM Imidazole, followed by elution of bound protein with 3 × 1 CV of Elution Buffer (Lysis Buffer + 250 mM Imidazole). Eluted fractions were pooled and dialysed overnight against 4li of 50 mM Hepes;pH 7.5, 300 mM NaCl, 1 mM TCEP with the addition of TEV protease to effect in-situ cleavage of the N-terminal 6His-GST tag. TEV cleaved solution was passed through a 0.5 ml NiNTA and the flow-through collected and concentrated 3--5 fold to give 4--10 mg/ml samples which were aliquotted and stored frozen at −80C.

In vitro irCLIP RNA binding {#s4-17}
---------------------------

In vitro irCLIP-seq was performed similarly to in vivo irCLIP with the following modifications. First, nuclear RNA was isolated as previously described ([@bib14]). Briefly, cells were pelleted and resuspended in Hypotonic Lysis Buffer (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl~2~, 0.3% NP-40 and 10% glycerol) with 100 Units SUPERase-In. Cells were incubated on ice for 10 min, vortexes, and centrifuged for 3 min at 1000xg at 4C. The pelleted nuclei were then washed 3x in hypotonic lysis buffer and centrifuged for 2 min at 200xg at 4C. Pellet was then resuspended in TRIzol and RNA extraction was carried out per the manufacturer's instructions. 20 μg nuclear RNA was then fragmented (Ambion, AM8740), and incubated with 5 μg recombinant Spen RRMproteins (RRM2-4 WT or RRM2-4:RRM3 Mt) at 4C for 2 hr. RNA-protein complexes were then transferred to a 3 cm cell culture dish on ice and crosslinked (254 nM UV-C) at 0.3 J/cm^2^. Following crosslinking, RNA-protein complexes were incubated with antibody-bound Protein A Dynabeads (anti-FLAG \[Sigma Aldrich F3165\] or anti-IgG) at 4C for 2 hr. Following IP, beads were washed with IPP buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.05% NP-40, 5 mM EDTA), low salt buffer (10 mM Tris-HCl pH7.4, 50 mM NaCl, 1 mM EDTA, 0.1% NP-40), and high salt buffer (10 mM Tris-HCl pH7.4, 500 mM NaCl, 1 mM EDTA, 0.1% NP-40, 0.1%SDS). After washes, the protocol was performed exactly as in in vivo irCLIP from dephosphorylation to membrane imaging(above).

irCLIP quality control analysis of endogenous SPEN {#s4-18}
--------------------------------------------------

irCLIP was performed as previously described ([@bib57]). In brief, 50% confluent WT and KO mESCs were UV-C crosslinked on ice with 0.3 J/cm2 and then lysed on-plate with 1 ml of lysis buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 1% Igepal CA-630, 0.5% NaDeoxycholate, 1 mM EDTA). Lysates were sonicated for 10 s (1 s on 1 s off) at 10% power with a Branson Digital Sonifier and clarified for 10 min at 13,500 rpm. Protein concentrations were quantified with the Pierce BCA assay. For RNAse digests, ice cold lysates were adjusted to 2 mg/ml and incubated with RNAse1 at a final concentration of 0.025 u/ml for 7.5 min at 37C. Reactions were stopped by addition of 1 ml of ice cold lysis buffer. For all immunoprecipitations, 3 ug of control IgG or anti-SPEN antibody were incubated overnight with 500 ug of lysates containing 30 ul of Protein G Dynabeads. Following irCLIP washes, immunoprecipitations were 3' dephosphorylated for 30 min and then ligated overnight with 1 pmole of irCLIP adapter. Immunoprecipitations were then rinsed once with ice cold PBS and then resuspended in 1 x LDS buffer containing 10 mM DTT and heated at 75C for 15 min prior to SDS-PAGE.

Analysis of expressed repeats in RNA-seq data {#s4-19}
---------------------------------------------

To identify expressed transposable elements in RNA-seq data, we counted all unique reads mapping to the database of repeat element loci from RepeatMasker for the mm9 genome. Bedtools multicov was used to count the number of reads per sample in each element. Read counts were then converted to fpkm. All elements with an FPKM \>= 1 in all samples were considered expressed and used for downstream analysis.

ERV knock-in at the *Xist* A repeat {#s4-20}
-----------------------------------

For Xist rescue experiments with ETn elements, we utilized the TXY ΔA cells which harbor a doxycycline inducible Xist transgene with the A Repeat region deleted. We designed donor plasmids for homology directed repair containing homology arms to the transgenic Xist present in TXY ΔA cells that contain a 154 bp portion of an ETn that binds to Spen, repeated 9x. Homology arms flanking the ETn insertions were cloned into the PCR4-Blunt TOPO vector (Thermo Fisher K287520). Cells were then nucleofected with a Cas9 RNP complex directed to the A Repeat region. 10 ug Cas9 protein (PNA Bio CP01-20) was mixed with 10 ug modified guideRNA (Synthego, GCGGGATTCGCCTTGATTTG) and 20 ug HDR donor vector. Cells were nucleofected with RNP complex and donor vector using the Amaxa Nucleofector (Lonza VPH-1001). Clonal colonies were picked and genotyped by PCR followed by Sanger sequencing. PCR of the Tet operator array was done using the following primers: TetO-F: 5'CCTACCTCGACCCGGGTACC3', TetO-R: 5'GGCCACTCCTCTTCTGGTCT3'.

RIP-qPCR {#s4-21}
--------

TXY WT, TXY ΔA, and TXY-ERV Clones 1 and 2 were transduced with a lentivirus carrying Spen RRMs 2--4 with the SV40 nuclear localization signal, 2x HA tags, and 3x FLAG tag ('SpenRRM-FLAG'; pLVX-EF1a-SV40NLS-SpenRRM234-2xHA-3xFLAG-IRES-zsGreen). Following transduction, GFP+ cells were FACS sorted and expression of the RRM-FLAG construct was confirmed by Western Blot using an anti-FLAG antibody (Sigma F3165). SpenRRM-FLAG expressing cells were treated with 10 mM HDAC1/2 inhibitor (Cayman Chemical Company, BRD6688, 1404562-17-9) for 24 hr, followed by treatment with HDAC1/2i + 2 mg/mL doxycycline for 24 hr. 5 million cells were then washed in PBS and lysed in RIP lysis buffer (50 mM Tris pH 8.0, 100 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 cOmplete Protease inhibitor tablet) in the presence of RNAse inhibitor (Thermo Scientific, RiboLock RNAse Inhibitor, EO0382). Cells were sonicated on a Covaris (Fill level 10, Duty Cycle 5%, PIP 140 Watts, 200 cycles/burst, 5 × 1 min/sample), and debris was pelleted for 15 min at 21,000xg at 4'C. Cleared supernatant was then added to 100 uL FLAG magnetic beads (Sigma, anti-FLAG M2 Magnetic Beads, M8823). After 2 hr incubation at room temperature, beads were washed three times in cell lysis buffer and resuspended in Trizol. RNA was extracted using the RNEasy mini kit (Qiagen, 74106). qRT-PCR was run on a Roche Lightcycler 480 using the Brilliant II SYBR Green qPCR Master Mix (Stratagene, 600804) using the following primers: Xist-F: 5'GCTGGTTCGTCTATCTTGTGGG3', Xist-R: 5'CAGAGTAGCGAGGACTTGAAGAG3', ActB-F: 5'TCCTAGCACCATGAAGATCAAGATC3', ActB-R: 5'CTGCTTGCTGATCCACATCTG3'.

Multimapping for repeat-derived reads in ChIP-seq and ATAC-seq data {#s4-22}
-------------------------------------------------------------------

After finding that SPEN regulates repeat regions, we re-analyzed the ChIP-seq and ATAC-seq data to include repetitive regions, which are usually removed in the standard analysis. We allowed each multimapping read to randomly assign to one place in the genome, without filter reads by mapping quality. The differential peaks is consistent to the results from unique mapped reads. We used the alignment files with multiple mapped reads for all the meta-analysis to avoid losing information.

Evolutionary analysis of spen {#s4-23}
-----------------------------

Multiple alignments of the SPEN CDS sequence were download from UCSC, including human, chimpanzee, rhesus, mouse, dog, opossum, platypus, chicken, zebrafish. We separated the CDS of SPEN into three domain regions (RID, SPOC and RRM).

We estimated the number of nonsynonymous substitutions per nonsynonymous site (*dN*), the number of synonymous substitutions per synony- mous site (*dS*), and the *dN*/*dS* ratio, for each region using maximum likelihood as implemented in the codeml program of the PAML software package ([@bib56]; [@bib25]). Model 0 were used to estimate the global evolution rate and model one were used to estimate branch specific evolution rate.

Integrated analysis of ChIP-seq, RNA-seq, and ATAC-seq data {#s4-24}
-----------------------------------------------------------

Differentially expressed genes were identified from RNA-seq data. The 1 kb region around the promoter of differentially expressed genes were used to count the signal from ChIP-seq and ATAC-seq data. The fold change of gene expression, histone modification and chromatin accessibility between WT and *Spen* KO were compared using a R package, named tableplot ([@bib52]).

The average plots and heatmap from histone modification, RNA expression, accessibility for interested regions were made using R package ngsplot ([@bib45]).

Repeat divergence analysis {#s4-25}
--------------------------

The divergence scores were download from repeatMasker through UCSC genome browser. We separated the ETn family by repeats with binding sites detected from irCLIP or not and the divergence score from mismatches (as a percentage) were compared. icSHAPE data analysis.

The icSHAPE data from Sun et al. were downloaded from GEO under accession GSE117840. The sequence data reads were collapsed to remove PCR duplicates and trimmed to remove 3' adapters following the icSHAPE computational pipeline ([@bib13]). The processed reads were mapped to the expressed repeat sequence using bowtie2 with parameters suggested by [@bib13]. The icSHAPE score were then calculated following the previous description. Repeat sequence with read depth more than 75 were kept for the following analysis. The icSHAPE score of SPEN binding sites and their flanking region(+ / - 20 bp) were extracted, The aggregated icSHAPE activity score were plotted for each base across non-overlapped binding locations on the Ent repeats.

irCLIP sequencing data processing {#s4-26}
---------------------------------

Sequencing output reads were processed by bbmap to remove the duplication on fastq level ([@bib47]). Remained reads were trimmed off the 3' solexa adapter and against the sequencing quality q20 by cutadapt (version 2.4). Trimmed reads were mapped first to the RNA biotypes with high repetitiveness by bowtie2 (version 2.2.9) to our custom built indexes: rRNAs (rRNAs downloaded from Ensembl NCBI37/mm9 and a full, non-repeat masked mouse rDNA repeat from GenBank accession No.BK000964), snRNAs (from Ensembl NCBI37/mm9), miscRNAs (from Ensembl NCBI37/mm9), tRNAs (from UCSC table browser NCBI37/mm9), retroposed genes (RetroGenes V6) and RepeatMasker (from UCSC table browser NCBI37/mm9). Remained reads were mapped to the mouse genome NCBI37/mm9 by STAR (version 2.7.1a) with junction file generated from mRNAs and lncRNAs of the Genocode NCBI37/mm9 GTF file. Only reads uniquely mapped to the mouse genome were included in the down-stream analysis. Mapping output files were transformed into bam files (samtools/1.9) and bed files (bedtools/2.27.1) for downstream analysis ([@bib47]).

SPEN binding cluster identification {#s4-27}
-----------------------------------

The RBP binding loci as suggested by the irCLIP method, was defined as one nucleotide shift to the 5' end of each mapped read. Each loci was extended five nucleotides both up and downstream into a 11-nt-long local interval. Only intervals overlapped between two biological replicates were considered reliably detected and were included in the downstream analysis. Overlapping intervals were merged into one cluster. Five nucleotides were trimmed from each side of the cluster to shape the final cluster boundary. Cluster length is required to be longer than one nucleotide for downstream analysis.

SPEN binding clusters on mouse genome and on repeat-regions were identified respectively. Cluster annotations were processed against the Genocode NCBI37/mm9 GTF file and RepeatMasker.

For each experiment condition of each cell type, only clusters with quantification tenfold higher than the observation in its corresponding IgG samples, would be included for the downstream analysis.

Gene/repeat element level quantification of SPEN binding {#s4-28}
--------------------------------------------------------

Quantification of SPEN binding on each expressed gene or expressed repeat element was calculated as the total amount of read in all binding clusters covering the gene/repeat element. The quantifications were then normalized by gene/repeat expression level.

SPEN binding RNA motif analysis {#s4-29}
-------------------------------

RNA motif enrichment analysis were process on SPEN binding clusters on mouse genome and on repeat-regions respectively (Homer version 4.10). Strand-specific sequences defined by SPEN irCLIP clusters were searched for short sequences elements 5-mer, 6-mer, 7-mer and 8-mer in each analysis of hypergeometric enrichment calculations. The searching background was set as expressed transcriptome and expressed repeat regions.

RNA 2D-structure {#s4-30}
----------------

2D-structures were predicted by the RNAstructure tool (version 6.0.1) with the maximum free energy model and according the icSHAPE results. 2D-structures of MMETn repeat1125276, ETnERV repeat355428 and RLTR13G_2D were process by algorithm AllSub. 2D-structure of Xist repeat A region \#4 and \#5 were processed with algorithm DuplexFold.

Cloning of wild-type and mutant spen RRMs 2--4 for in vitro biochemistry {#s4-31}
------------------------------------------------------------------------

Wild type mouse Spen cDNA was kindly provided in a D-TOPO vector from the Guttman lab (Caltech). Mutant Spen cDNA corresponding to RRMs 2--4 (F442A, K471A, Y479A, F481A, K513A) was ordered as a gBlock from IDT (Coralville, IA). Primers containing SalI and XhoI restriction enzyme cut sites on the 5'-end and 3'-end respectively of the cDNA corresponding to RRMs 2--4 (aa 336--644) were used to PCR amplify both wild type and RRM3 Mt cDNA inserts for ligation into a pET28b vector containing an N-terminal 10xHis-SUMO tag using the Quick Ligation kit (NEB, Ipswich, MA). Plasmids containing the cDNA of interest were verified by Sanger sequencing prior to expression (Quintara Biosciences, San Francisco, CA).

Expression and purification of wild-type and mutant spen RRMs 2--4 for in vitro biochemistry {#s4-32}
--------------------------------------------------------------------------------------------

BL21(DE3) expression cells were transformed with pET28b vector containing the cDNA of the protein of interest. 1 L cultures of 2XYT media were grown at 37°C for 3 hr to an OD~600~ between 0.6--1.2. Cells were flash-cooled on ice for 10 min, then 1 mM IPTG was added to induce protein expression overnight at 20°C. Cells were harvested, and pellets were frozen and stored at −20°C until purification. All proteins were subject to a 3-column purification protocol; the wild-type buffers were pH 7.5, while the mutant buffers were pH 8.3 due to differences in predicted pI and anticipated solubility requirements. Specifically, one cOmplete EDTA-free EASYpack protease inhibitor tablet (Roche, Basel, Switzerland) was added to each cell pellet corresponding to 1 L of growth. The tablet and frozen cell pellet were resuspended in 80 mL of lysis buffer (750 mM KCl, 750 mM NaCl, 1 M urea, 50 mM Tris, 10% glycerol, 10 mM imidazole, 1% triton X-100). The cell slurry was sonicated on ice with a Misonix Sonicator 3000 (Misonix, Farmingdale, NY) for 4--6 total minutes in pulses of 15 s followed by 35 s of rest. Membranes and other cellular debris were sedimented away from soluble protein on a Beckman J2-21 large floor centrifuge (Beckman Coulter, Brea, CA). Supernatant containing the recombinant protein was incubated with 10 mL of precleared Ni-NTA beads for 10 min at 4°C. Unbound cellular proteins were cleared by gravity flow. Beads were washed twice; once with 150 mL of lysis buffer, and once with 100 mL of modified lysis buffer containing 20 mM imidazole. Protein was then eluted with 50 mL of similar buffer containing 300 mM imidazole. For the washes and elution, beads were resuspended and incubated with the buffer for 10 min prior to gravity flow through. The elution was dialyzed in 4 L of size exclusion column buffer (500 mM urea, 270 mM KCl, 30 mM NaCl, 50 mM Tris, 7% glycerol, 1--2 mM DTT) for about 2 hr at 4°C. 1--2 mL of 1 mg/mL in-house His-ULP1 \[Mossessova and Lima, Mol. Cell (2000), 865--876\] was then added, and SUMO tag cleavage of recombinant Spen protein and further dialysis continued overnight at 4°C. Protein precipitate, when present, was pelleted or filtered prior to flowing over the second Ni-NTA column (11 mL beads precleared in column buffer). The Spen fragment flowed through the second Ni column while the His tagged protease and SUMO expression tag were retained on the resin. Flowthrough containing the cleaved Spen construct was concentrated to 2 mL for injection onto the Superdex 200 size exclusion column. Size exclusion fractions are checked for the presence of purified protein by SDS-PAGE. Fractions containing purified protein are combined, concentrated to between 100 µM - 1 mM, aliquoted, flash frozen in liquid nitrogen, and stored at −70°C until binding assays are performed.

RNA generation cDNAs of RNAs of interest with a 5' T7 promoter were ordered as gBlocks from IDT (Coralville, IA). Primers flanking the cDNA containing the EcoRI and BamHI cut sites on the 5' and 3' ends respectively were used to PCR amplify the cDNA for restriction enzyme cloning into a pUC19 vector for cDNA amplification. Ligated plasmids were verified using Sanger sequencing (Quintara Biosciences, San Francisco, CA) and utilized for transcription template generation. Standard PCR using a 3' transcription primer was used to generate in vitro transcription template for run-off transcription. For in vitro transcription, 300 nM PCR template was incubated at 37°C for 2--4 hr with 4 mM each rNTP in 24 mM Mg^2+^, 40 mM Tris pH 8.0, 10 mM DTT, 2 mM spermidine, 0.01% Triton X-100, IPPase (\>0.01 U/µL), and in-house T7 polymerase (Batey Lab, CU Boulder). Transcription reactions were gel purified on a 5--12% acrylamide 8M urea 1X TBE slab gel. Reaction products were UV shadowed, appropriate sized bands were excised, and RNA was extracted through a 0.5X TE crush and soak (4°C, 1 hr). Gel bits were filtered and RNA was buffer exchanged in 0.5X TE until the calculated residual urea was less than 10 µM. RNA was concentrated prior to use; purity and concentration were assessed by the A~260~ and the A~260~/A~280~ ratio. Concentrations were calculated using the extinction coefficient provided for each RNA sequence by the Scripps extinction coefficient calculator (<https://www.scripps.edu/researchservices/old/corefac/biopolymercalc2.html>).

FTSC 3'-end labeling of RNA {#s4-33}
---------------------------

350 pmol of purified RNA were treated with 20 mM NaIO~4~ for 20 min in the dark at room temperature. Excess NaIO~4~ was precipitated using 26 mM KCl (10 min on ice followed by a hard spin). Supernatant containing the RNA was then ethanol precipitated with the aid of 1 µg glycogen. The RNA pellet was washed 1x with 70% ethanol, and then resuspended in 100 µL of freshly made labeling solution (1.5 mM FTSC, 10% DMF, 100 mM NaOAc pH 5.2) and reacted at 37°C in the dark for 1--2 hr. 280 µL of cold 100% ethanol was then added to precipitate the RNA (ice for ≥30 min). The labeled RNA pellet was then washed thoroughly at least 4X with 400 µL of 70% ethanol, resuspended in 30 µL of water, and run through a Sephadex MicroSpin G-25 column (GE Healthcare) to remove excess FTSC. Labeled products were qualitatively assessed for purity and labeling efficiency via denaturing gel analysis; the Cy2 filter on the Typhoon imager (GE Healthcare) was used to visualize the attached fluorophore. A~260~ measurements post-labeling were used to determine RNA concentration. Labeling efficiencies typically allowed for the use of RNA in binding assays between 1--3 nM. FTSC-labeled RNA was stored in dark amber tubes at −20°C until use.

Fluorescence anisotropy (FA) binding assays {#s4-34}
-------------------------------------------

Wild-type and mutant Spen binding were performed at pH 7.5 and 8.3 respectively. RNA concentrations were held as low as possible while still obtaining enough fluorescent signal (1--3 nM). Briefly, purified labeled RNA was snap cooled in 1X binding buffer (45 mM KCl, 5 mM NaCl, 50 mM Tris, 5% glycerol) at 2X the final concentration, and likewise protein titrations were performed separately in 1X binding buffer at 2X final concentration. Protein and RNA were then mixed in a 1:1 vol ratio in a 20 µL reaction and were allowed to come to equilibrium at room temperature in the dark for 40--60 min. Flat bottom low flange 384-well black polystyrene plates (Corning, Corning, NY) were used. Perpendicular and parallel fluorescence intensities (I~⊥,~I~‖~) were measured using a ClarioStar Plus FP plate reader (BMG Labtech). Anisotropy values were calculated for each protein titration point where anisotropy = (I~‖~ - I~⊥~)/(I~‖~ + 2\*I~⊥~). Protein concentration was plotted versus associated anisotropy, and data were fit to the simplified binding isotherm (anisotropy \~fraction bound=S\*(P/(K~D~+P))+O with KaleidaGraph where S and O were saturation and offset respectively, and P was the protein concentration.

^32^P 5'-end labeling of RNA {#s4-35}
----------------------------

50 pmol of RNA were treated with calf intestine phosphatase (NEB) for 1 hr at 37°C. RNA was purified via phenol chloroform extraction followed by ethanol precipitation. RNA was resuspended and γ-ATP was added to the 5' end of the RNA with T4 polynucleotide kinase (NEB) for 30 min at 37°C. Water was added to dilute the RNA to 1 µM, and the reaction was then run through a Sephadex MicroSpin G-25 column (GE Healthcare) to remove excess γ-ATP. ^32^P-labeled RNA was stored at −20°C.

Competition assay {#s4-36}
-----------------

Wild-type Spen and ^32^P-labeled A repeat concentrations were kept constant at 10 µM and 1 µM respectively, and the competition was done at 50 mM Tris (pH 7.5), 45 mM KCl, 5 mM NaCl, and 2.5% glycerol. Different amounts of unlabeled competitor RNA were added, and the amounts were relative to the amount of labeled RNA. Briefly, RNAs were snap cooled in RNA buffer (50 mM Tris (pH 7.5), 45 mM KCl, 5 mM NaCl). Labeled RNA was snap cooled at 4X the final concentration, while competitor RNA was snap cooled at 2X the final concentration. Protein was diluted in protein buffer (50 mM Tris (pH 7.5), 45 mM KCl, 5 mM NaCl, 10% glycerol) to 4X the final concentration. 2.5 µL of 4X protein, 2.5 µL of 4X labeled RNA, and 5 µL of 2X competitor RNA were allowed to come to equilibrium at room temperature for 40--60 min. The reactions were then loaded onto a pre-run 5% acrylamide 0.25X TBE mini native gel at 200V. The gel was run at room temperature at 200V for 10--15 min, dried, then exposed overnight to a phosphoscreen. Phosphoscreen images were taken on the Typhoon (GE Healthcare) at 50 µm resolution.

List of RNA sequences used in direct binding and competition {#s4-37}
------------------------------------------------------------

1.  A-repeat from Xist (85 nt): GGAACTCGTTCCTTCTCCTTAGCCCATCGGGGCCATGGATACCTGCTTTTAACCTTTCTCGGTCCATCGGGACCTCGGATACCTG

2.  SRA RNA (82 nt): GGAGCAGGTATGTGATGACATCAGCCGACGCCTGGCACTGCTGCAGGAACAGTGGGCTGGAGGAAAGTTGTCAATACCTGTA

3.  ERV 205 (86 nt):

4.  GAUUCCAGGCAGAACUGUUGAGCAUAGAUAAUUUUCCCCCCUCAGGCCAGCUUUUUCUUUUUUUAAAUUUUGUUAAUAAAAGGGAG

5.  ERV 509 (114 nt):

6.  GGUUAAAACUGCUAUUGUUCCAUUGACUGCAGCUUGCAGUUUGAUUUCAAAUUUAAGAUCUUUAAUUCACCUGUAUACUGUAAUUAAGAUAAUUACAAGAGUAAUCAUCUUAUG

7.  ERV 495 (113 nt):

8.  GAAAUUUCUCUCUGGGCCUUAUAGCAGGAGUACUCUGUUCCCUUUUGUGUCUUGUCUAAUGUCCGGUGCACCAAUCUGUUCUCGUGUUCAAUUCAUGUAUGUUCGUGUCCAGU

9.  ERV 411 (109 nt):

10. GGUACCUUAAAUCCUUGCUCUCACCCAAAAGAUUCAGAGACAAUAUCCUUUUAUUACUUAGGGUUUUAGUUUACUACAAAAGUUUCUACAAAAAAUAAAGCUUUUAUAA

11. ERV 302 (111 nt):

12. GAUCAGAGUAACUGUCUUGGCUACAUUCUUUUCUCUCGCCACCUAGCCCCUCUUCUCUUCCAGGUUUCCAAAAUGCCUUUCCAGGCUAGAACCCAGGUUGUGGUCUGCUGG

Code availability statement {#s4-38}
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Spen links RNA-mediated endogenous retrovirus silencing and X chromosome inactivation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Gene W Yeo as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by James Manley as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Molly Hammell (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Carter et al. demonstrates that SPEN, an RNA binding protein involved in *Xist* interaction, also binds to ERV elements embedded in transcripts. Structurally, ERV elements appear to be similar to the SPEN binding site in *Xist*. The authors provide data that indicate SPEN represses ERV elements in mouse ES cells. Inactivation of SPEN leads to increase in chromatin accessibility, active histone marks and RNA transcription of ERV element-encoded transcripts. The authors identify that RRM3 domain of SPEN is responsible for binding to ERV and insertion of ERV into an A-repeat deficient *Xist* can rescue binding of *Xist* RNA to SPEN, which result in local gene silencing. Overall the paper is an interesting observation that has for the most part rigorous assays that contribute to our understanding of how *Xist* evolved new domains to recruit protein interactors for gene expression control. There are, however, major concerns that need to be addressed.

Major concerns:

1\) Can the authors clarify how the chromatin changes observed at ERV genomic loci change upon SPEN depletion in mESCs as there are some inconsistencies. The high expression of the ERV elements in WT ESCs would be expected to reflect open chromatin at these loci. But are these ERVs then repressed normally? The model of RNA recruitment of SPEN to the ERVs can be better explained to account for these inconsistencies. Also, what fraction of the ERVs with altered chromatin marks have associated expressed transcripts and which ones are differentially expressed in SPEN KO cells? Can the authors present the data as standard DEseq-like scatter/volcano plots?

2\) The preference for ERVs, and especially ERV-K\'s is still unclear. The only thing that links ERVK type TEs to each other is the presence of a lysine-tRNA in the primer binding site (PBS) of those ERV internal sequences. So, given that SPEN is not looking for a specific sequence, but a structure. And, given that SPEN doesn\'t seem to care about the ERV PBS region, it is difficult to understand why it prefers ERVK elements. Can the authors show that these are structurally different than the other TEs that are not bound? Eg., do they lack the single stranded bubbles associated with SPEN preferred shapes? Or, are these really just following what\'s expressed at this stage?

3\) The results from the experiments replacing the A-repeat in *Xist* with the ERV sequence needs more clarification. The RIP-PCR data does not appear to demonstrate significant binding of SPEN to ERV-XIST for clone 1 and the CLIP-PCR data in the supplement does not show significance testing and have differing data between the two *Xist* primer pairs. The results regarding the repression of ERV-XIST needs to be clarified. It seems that HDAC1/2 inhibition has the largest effect on derepression, even though SPEN is thought to function through HDAC3 in XCI. Which HDACs might be involved in SPEN recruitment to ERV-XIST? In that same line of inquiry, the authors should explain some inconsistencies. They report SPEN induces silencing of the *Xist* RNA instead of silencing the *Xist*-bound chromosome. This suggests that there is some information that could be useful in the comparisons between which TEs were directly bound in the Clip-seq data, which of them had chromatin-based alterations, and which induced changes at the RNA level. There should have been one summary figure of the genomics data that shows how consistent these are with each other. Perhaps what happens at a locus depends on where SPEN binds (on the LTR promoter elements vs. internally)? Perhaps the number of SPEN binding sites on the locus influences how those transcripts are regulated (as they seem to be hinting at in Figure 6E)? Even if this can\'t explain why SPEN seems to regulate TEs differently from how it contributes to XCI, these comparisons should be explored.
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Author response

> Major concerns:
>
> 1\) Can the authors clarify how the chromatin changes observed at ERV genomic loci change upon SPEN depletion in mESCs as there are some inconsistencies. The high expression of the ERV elements in WT ESCs would be expected to reflect open chromatin at these loci. But are these ERVs then repressed normally? The model of RNA recruitment of SPEN to the ERVs can be better explained to account for these inconsistencies. Also, what fraction of the ERVs with altered chromatin marks have associated expressed transcripts and which ones are differentially expressed in SPEN KO cells? Can the authors present the data as standard DEseq-like scatter/volcano plots?

The reviewers make a great point, that the relationship between changes in chromatin accessibility or modifications and RNA expression can be better presented. In general, there is low but detectable level of ERV RNA expression in wild type cells. In *Spen* KO cells, some ERV loci gain chromatin access, lose heterochromatic marks, and have elevated RNA expression. These results are consistent with a Spen-mediated surveillance of ERV loci via RNA. We now present this data in Figure 2---figure supplement 1A-F. In panels a-c, we show that there are family-specific changes in chromatin accessibility, H2K9me3 modification, and expression of specific subfamilies of transposable element as determined by DESeq2 in *Spen* KO mESCs. In panels d-f, we show the changes in RNA expression and chromatin modification at the sites that gain accessibility in *Spen* KO mESCs. Consistent with the data presented in Figure 2, we demonstrate that sites gaining accessibility in *Spen* KO mESCs show increased RNA expression, increased enhancer-associated marks (H3K27Ac), and decreased repressive marks (H3K9me3).

> 2\) The preference for ERVs, and especially ERV-K\'s is still unclear. The only thing that links ERVK type TEs to each other is the presence of a lysine-tRNA in the primer binding site (PBS) of those ERV internal sequences. So, given that SPEN is not looking for a specific sequence, but a structure. And, given that SPEN doesn\'t seem to care about the ERV PBS region, it is difficult to understand why it prefers ERVK elements. Can the authors show that these are structurally different than the other TEs that are not bound? Eg., do they lack the single stranded bubbles associated with SPEN preferred shapes? Or, are these really just following what\'s expressed at this stage?

The reviewers raise a good point, that Spen's apparent preference for ERVKs cannot be explained entirely by their belonging to the ERVK family of TEs. We believe that Spen's specificity for this subset of ERVK subfamilies has at least two components: (i) the developmental stage during ES cell differentiation, and (ii) the structure of the recognition site on the RNA. First, we observed that Spen does not bind to nor repress all ERVKs. Rather, only specific subsets of ERVK families are targeted, notably the ETn family and RLTR9 and 13 (Figure 2C and Figure 2---figure supplement 1). These subsets of ERVKs have the potential to be expressed in the mESC state, and thus are not as heavily repressed by DNA methylation and other chromatin modifications as other TE families. Thus, they may display some aberrant transcription in mESCs, leading Spen to recognize their RNA products and recruit silencing machinery to silence the locus. Consistent with this idea, we see ectopic occupancy of Oct4, the pluripotency transcription factor on these subsets of ERVKs (Figure 2A, 2B).

Second, within each of these TE subfamilies we find that the elements with the strongest RRM binding in *Spen* KO mESCs show the highest expression level ([Author response image 1A, B](#respfig1){ref-type="fig"}). Despite these TE families being highly expressed, there are other TE families that show high expression but low Spen binding, suggesting that structural features in TE RNAs also contribute to Spen's ability to recognize them ([Author response image 1C](#respfig1){ref-type="fig"}). It is difficult to assess the structural features of TEs that are not bound by Spen. For Spen-bound TEs, we know the specific Spen binding site from our irCLIP-seq data and can use the sequence in that specific region to assess RNA structure from icSHAPE and RNA folding models. For unbound TEs, the entire length of the ERVK RNA contains many secondary structures (predicted), so it is difficult to assess which regions are appropriate to compare to the Spen binding sites on bound RNAs. Nonetheless, the Spen irCLIP-seq data show that the RRM binding is highly focal within ETnERV and Xist RNAs (Figure 4), which correspond to specific RNA secondary structures with a GC-rich dsRNA regions interspersed with single-stranded RNA bases. This specificity is consistent with the known RNA binding specificity of Spen RRM (Arieti et al., 2014; Lu et al., 2016).

![Relationship between expression and Spen RRM binding for ERV RNAs.\
(**a**) Scatter plot showing the number of RT stops from irCLIP-seq vs. the expression from RNA-seq for all expressed MMETn-int elements. (**b**) Same as in a for all ETnERV elements. (**c**) Table displaying the ERV elements that are expressed in WT or Spen KO mESCs. Columns display the number of expressed elements, the number bound by Spen, the percentage bound by Spen, and the expression rank amongst all ERV families.](elife-54508-resp-fig1){#respfig1}

> 3\) The results from the experiments replacing the A-repeat in Xist with the ERV sequence needs more clarification. The RIP-PCR data does not appear to demonstrate significant binding of SPEN to ERV-XIST for clone 1 and the CLIP-PCR data in the supplement does not show significance testing and have differing data between the two Xist primer pairs. The results regarding the repression of ERV-XIST needs to be clarified. It seems that HDAC1/2 inhibition has the largest effect on derepression, even though SPEN is thought to function through HDAC3 in XCI. Which HDACs might be involved in SPEN recruitment to ERV-XIST? In that same line of inquiry, the authors should explain some inconsistencies. They report SPEN induces silencing of the Xist RNA instead of silencing the Xist-bound chromosome. This suggests that there is some information that could be useful in the comparisons between which TEs were directly bound in the Clip-seq data, which of them had chromatin-based alterations, and which induced changes at the RNA level. There should have been one summary figure of the genomics data that shows how consistent these are with each other. Perhaps what happens at a locus depends on where SPEN binds (on the LTR promoter elements vs. internally)? Perhaps the number of SPEN binding sites on the locus influences how those transcripts are regulated (as they seem to be hinting at in Figure 6E)? Even if this can\'t explain why SPEN seems to regulate TEs differently from how it contributes to XCI, these comparisons should be explored.

We apologize for the confusion regarding the Xist-ERV experiments and hope to clarify here and in the main manuscript text. First, we observed that expression of *Xist-ERV* was significantly reduced compared to *Xist-WT* or *Xist-*△*A* upon doxycycline treatment and we found that this failure to induce the chimeric *Xist* RNA was due to epigenetic silencing and not genetic changes in the Tet operator in our cells (Figure 6---figure supplement 2D-G). Recent work from Edith Heard's lab (Zylicz et al., 2019) showed that HDAC3 inhibition partially blocks X chromosome inactivation. Interestingly, they also found that HDAC1/2 inhibition leads to upregulation of transgenic *Xist* through epigenetic derepression. Thus, we tested whether HDAC1/2i or HDAC3i could relieve Spen-mediated silencing of *Xist-ERV*. We found that both HDAC1/2 and HDAC3 relieved Spen-mediated *Xist* repression, and chose to perform functional experiments in the presence of HDAC1/2i, since we knew this would allow expression of our chimeric *Xist* presumably without affecting the ability of this lncRNA to silence the X chromosome which we wished to test. Our data also indicate that Spen and HDAC3 are responsible for *Xist-ERV* mediated gene repression, as the repression is relieved by knock down of Spen and inhibition of HDAC3 (Figure 6D).

We also wish to clarify the results of the Spen RRM RIP experiments with Xist-ERV clone 1. Even in the presence of HDACi, *Xist-ERV* expression was significantly lower than the expression of *Xist-WT*, making the RIP-qPCR results for this cell line significantly noisier than those obtained with Xist-WT. The results are plotted as the percent of input RNA, and in the case where the input RNA is lowly expressed, this value is inherently noisier. While the result is not statistically significant, this is driven in large part by two outliers (one high and one low, of 6 total). Thus the results for Xist-ERV clone 1 suggest that Spen RRM binds to Xist-ERV and the results from clone 2 show that Spen RRM binding to Xist-ERV is significant.

In [Author response image 2](#respfig2){ref-type="fig"} and in Figure 6B, we now present the results of the Spen RRM RIP-qPCR experiments excluding the highest and lowest replicates for each sample, including all controls. Due to the low levels of *Xist* expression, the noise in the assay warrants the removal of these outliers, as the experiment is operating at the lower bound of dynamic range. From this analysis, we conclude that the results in Xist-ERV clones 1 and 2 show that the Spen RRMs bind to *Xist-WT* and *Xist-ERV*, but not to *Xist-ΔA*.

![Spen RRM RIP-qPCR results with and without outlier correction (related to Figure 6b).\
(**a**) RIP-qPCR for Xist and ActB in Xist-WT, Xist-ΔA, and Xist-ERV clones 1 and 2 mESCs. qRT-PCR values are normalized to input samples. Error bars represent standard error for 4 independent biological replicates. The highest and lowest values for each sample were removed due to noise. P-values are derived from two-tailed t-test. (**b**) RIP-qPCR for Xist and ActB in Xist-WT, Xist-ΔA, and Xist-ERV clones 1 and 2 mESCs. qRT-PCR values are normalized to input samples. Error bars represent standard error for 6 independent biological replicates. No values were excluded from the analysis. P-values are derived from two-tailed t-test.](elife-54508-resp-fig2){#respfig2}

We also understand the confusion regarding the CLIP-qPCR presented in the supplemental figure. The reason that these panels did not have significance indicated is that they were performed with technical but not biological replicates. We opted to perform more experiments (n=6 biological replicates) for the RIP-qPCR instead of the CLIP-qPCR, so we have chosen to remove the CLIP-qPCR results from the manuscript. We don't believe this affects the results presented in Figure 6.

Regarding the mechanism by which Spen silences target loci, we believe that our results are consistent with a model in which Spen recognizes and binds certain transcripts, including ERV-derived transcripts, recruits silencing machinery, including HDACs, and silences the promoter. We provide the list of altered loci with each assay in Figure 2---figure supplement 1. This model is consistent with our results at ERVs as well as our results in the context of the *Xist-ERV* chimeric RNA.

The matter of the overlap between ERVKs bound by Spen RRMs (irCLIP-seq) and the ERVKs that become de-repressed at the level of chromatin modifications and RNA expression is complex. We find consistently that the sites that change at the chromatin and RNA level belong to specific subsets of ERVKs including ETns, and we found that these ERVK subfamilies are also bound by Spen RRMs in multiple cell lines and conditions (Spen FL and RRM-FLAG). However, we find very little overlap between the specific genomic loci that change in accessibility and produce RRM-bound transcripts (1/288 sites that gain accessibility). We believe that this is likely due to differences in when these experiments were performed and the passage of the cells used. For the irCLIP-seq experiments, cells had to be expanded, infected with RRM-FLAG viruses and subcloned. Thus, if Spen's recognition of ETns and other ERVKs is consistent, but the source of these aberrant expressed ETns in the genome is dynamic, the results are consistent with what we observe. Unfortunately, for technical reasons, these experiments were performed multiple passages apart.

A fascinating mystery of the X inactivation field is how *Xist* itself can be expressed from the inactive X chromosome when this lncRNA is recruiting multiple powerful gene silencing complexes. This duality of potent expression on the inactive X while silencing the remainder of the chromosome is an evolved function of the modern lncRNA. In the context of wild type *Xist*, Spen is able to bind to *Xist* and spread across the chromosome in order to silence distal gene promoters. We found that *Xist-ERV*, our model of a proto-Xist lncRNA, mainly executes cis silencing of its own locus. This implies that additional features are missing in *Xist-ERV*. We agree with the reviewer that the number or quality of RNASpen interaction may determine the difference between local vs. distant gene silencing. It is also worth recalling that *Xist* A-repeat interacts with m6A modification machinery (WTAP, RBM15) as well as RNF20 (Chu et al., 2015; Patil et al., 2016). Some of these interactions are likely missing in *Xist-ERV*. Very recently it was suggested that *Xist* A-repeat has transcriptional anti-terminator activity (Lee et al., 2020), that allows *Xist* RNA to be transcribed in the face of regulatory factors that normally terminate transcription. We believe that solving this longstanding mystery in the field is beyond the scope of the present work, and respectfully suggest our work has clarified the distinct functions that may be gained by a lncRNA when it exapts an endogenous retroviral element.
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